IGF2BP3 and glioblastoma: We further tested in selected glioblastoma cells and demonstrated that the application of dCas13b tethering systems (IGF2BP3 or METTL1) on TP53 could promote its decay and downregulate both the transcript and protein levels, which notably impact glioblastoma progression and chemotherapy resistance.